Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in Colorectal Cancer In Vitro and In Vivo

[1]  S. Kopetz,et al.  Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. , 2017, Cancer discovery.

[2]  J. Tímár,et al.  Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK , 2017, Front. Oncol..

[3]  C. Dreyer,et al.  BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? , 2017, Current Treatment Options in Oncology.

[4]  J. Tímár,et al.  KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models , 2016, Oncotarget.

[5]  G. Devi,et al.  Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. , 2016, Pharmacology & therapeutics.

[6]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[7]  S. McGuire.  World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. , 2016, Advances in nutrition.

[8]  M. Memo,et al.  The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines , 2016, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  P. Casey,et al.  Protein prenylation: unique fats make their mark on biology , 2016, Nature Reviews Molecular Cell Biology.

[10]  Kazuhiro Yoshida,et al.  Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status , 2015, International journal of cancer.

[11]  P. Gibbs,et al.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Jiang,et al.  Zoledronate can promote apoptosis and inhibit the proliferation of colorectal cancer cells , 2015, Tumor Biology.

[13]  W. Berger,et al.  Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells , 2015, PloS one.

[14]  Thomas D. Wu,et al.  A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.

[15]  Ling-Ling Zhu,et al.  Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer , 2014, Proceedings of the National Academy of Sciences.

[16]  E. Oldfield,et al.  A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin , 2014, Science Translational Medicine.

[17]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[18]  Delyan P. Ivanov,et al.  Multiplexing Spheroid Volume, Resazurin and Acid Phosphatase Viability Assays for High-Throughput Screening of Tumour Spheroids and Stem Cell Neurospheres , 2014, PloS one.

[19]  D. Cameron,et al.  Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. , 2014, The Lancet. Oncology.

[20]  Liam O'Connor,et al.  Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. , 2014, Cancer research.

[21]  Seyed Abbas Mirzaei,et al.  The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells. , 2014, Biochimie.

[22]  Guorong Yang,et al.  Oral Bisphosphonates and the Risk of Colorectal Cancer: A Meta-Analysis , 2013, Journal of clinical gastroenterology.

[23]  B. Manning,et al.  mTORC1 Status Dictates Tumor Response to Targeted Therapeutics , 2013, Science Signaling.

[24]  S. Bonovas,et al.  Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis. , 2013, British journal of clinical pharmacology.

[25]  L. Ayong,et al.  Chemo-Immunotherapeutic Anti-Malarials Targeting Isoprenoid Biosynthesis. , 2013, ACS medicinal chemistry letters.

[26]  Harminder Singh,et al.  Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Amadori,et al.  Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid , 2012, Cancer Cell International.

[28]  Larissa V Furtado,et al.  Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer , 2011, Genes, chromosomes & cancer.

[29]  K. Wanner,et al.  Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors. , 2011, European journal of medicinal chemistry.

[30]  A. Orlandi,et al.  Anti‐tumour and anti‐angiogenetic effects of zoledronic acid on human non‐small‐cell lung cancer cell line , 2011, Cell proliferation.

[31]  Hisao Ito,et al.  Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines. , 2011, Oncology reports.

[32]  L. Ste-Marie,et al.  Role of zoledronic acid in the prevention and treatment of osteoporosis , 2011, Clinical interventions in aging.

[33]  S. Gruber,et al.  Use of bisphosphonates and reduced risk of colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Fearon.  Molecular genetics of colorectal cancer. , 2011, Annual review of pathology.

[35]  G. Morgan,et al.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.

[36]  E. Raso,et al.  KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. , 2010, Current cancer drug targets.

[37]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[38]  S. Cross,et al.  Microvascular Endothelial Cell Responses in vitro and in vivo: Modulation by Zoledronic Acid and Paclitaxel? , 2010, Journal of Vascular Research.

[39]  K. Schaefer,et al.  Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.

[40]  K. Lau,et al.  Non-redundancy within the RAS oncogene family: Insights into mutational disparities in cancer , 2009, Molecules and cells.

[41]  Ting-Kai Chang,et al.  Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. , 2009, Journal of the American Chemical Society.

[42]  A. Schweitzer,et al.  Biodistribution and Plasma Protein Binding of Zoledronic Acid , 2008, Drug Metabolism and Disposition.

[43]  Florian Steinberg,et al.  The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis , 2008, Apoptosis.

[44]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[45]  C. Riebeling,et al.  Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells , 2004, British Journal of Cancer.

[46]  S. Kimura,et al.  p53‐independent anti‐tumor effects of the nitrogen‐containing bisphosphonate zoledronic acid , 2004, Cancer science.

[47]  C. Boland,et al.  Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro , 2003, British Journal of Cancer.

[48]  G. Pirianov,et al.  Bisphosphonates induce apoptosis in human breast cancer cell lines , 2000, British Journal of Cancer.

[49]  E. Pieterman,et al.  Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. , 1999, Biochemical and biophysical research communications.

[50]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[51]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.